Thymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a naturally occurring peptide derived from the thymus gland. It plays a central role in immune system regulation and has been studied for its ability to enhance immune responses in immunocompromised patients. It is approved as a medicine in several countries.
Quick facts
- Half-life
- ~2 hours
- Administration
- Subcutaneous injection
- Primary use
- Immune modulation, infection resistance
How it works
Thymosin Alpha-1 modulates T-cell activity, enhancing both innate and adaptive immune responses. It stimulates the maturation of T-cells in the thymus and increases the production of cytokines that coordinate immune defence.
Reported benefits
- Enhanced T-cell function and immune response
- Studied for use in chronic infections and immunodeficiency
- Anti-inflammatory properties in autoimmune contexts
- Approved for hepatitis B and C treatment in some countries
Typical dosing protocol
Dosing
1.6 mg subcutaneously, 2x per week for 6–12 months (clinical dosing); research protocols vary
Cycle length
Variable — often 6–12 weeks for research use
Dosing information is for educational reference only. Individual needs vary. Always consult a healthcare professional.
Safety & considerations
Well-tolerated with a strong clinical safety record. Approved as a medicine in Italy, China, and other countries. Not approved for human use in the UK outside of clinical trials. Consult a healthcare professional before use.
Important: All content is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.